… , which cost up to half a million US dollars (USD) per treatment [6]. … awareness about the
safety, efficacy, and appropriate use of … was given to potential knowledge gaps. The survey was …

… indicated for the active treatment of cancer. This suggests a deeper … of regulations and
knowledge with respect to biosimilars, see … and biosimilar through the use of co-payment or co- …

… difference of about 15%, and although oncologists initially expressed reluctance to use the
… care providers to improve knowledge and understanding of biosimilars and interchangeable …

… patients to assess their knowledge and attitudes toward … to a biosimilar, and educational
opportunities to understanding … describes the attitudes toward biosimilars in US patients with self-…

… alternatives exist, increasing patient co-payments, establishing … impact all aspects of the US
biosimilar market. Key regulatory … Stakeholder perspectives included biosimilar knowledge …

… is the knowledge that failure of first-line cancer treatment usually … may go down Where there
is partial access or with co-… for understanding biosimilar confirmatory trials: first, biosimilar …

… To our knowledge, this was the first cost analysis calculating … to biosimilar over one year
taking into account all patients from … among German physicians indicated awareness among the …

… , and better understanding of the role that biosimilars play as an … given their current state of
knowledge. Barriers to prescribing … Co-chairs of the Education Committee of the Biosimilars …

… largely attributed to poor knowledge of biosimilars and a lack of … Australian clinicians,
particularly in the field of oncology. … and co-workers suggested that, if a rituximab biosimilar had …

… According to a survey of 376 US oncologists, prescribers lacked knowledge and understanding
of the effects of biologic drugs and biosimilars that share the same nonproprietary name. …